Biomapas Acquires Delta PV to Expand Pharmacovigilance Capabilities

KAUNAS, Lithuania - Aug. 18, 2025 - PRLog -- Biomapas, a global contract research organization (CRO) serving the pharmaceutical and biotechnology industries, today announced the acquisition of Delta PV, a leading pharmacovigilance service provider headquartered in Istanbul, Turkey. The strategic move expands Biomapas' global safety capabilities and strengthens its presence in high-growth regions, including Europe, the Commonwealth of Independent States (CIS), Asia-Pacific (APAC), and the Middle East and North Africa (MENA).

Delta PV brings trusted global expertise in pharmacovigilance, offering end-to-end support from QPPV services to literature screening, signal detection, and compliance. Powered by its proprietary automated platform, Delta PV streamlines safety data monitoring—delivering a seamless, compliant, and digitally enabled solution for today's fast-paced life sciences environment.

"This acquisition marks an exciting milestone in Biomapas' growth journey," said David Passov, CEO of Biomapas. "By integrating Delta PV's scientific expertise and technology, we are further equipping our team to support clients in navigating an increasingly complex regulatory environment. We're thrilled to welcome Delta PV's highly skilled professionals into the Biomapas family."

Delta PV has earned a strong reputation for its science-driven and client-centric approach to pharmacovigilance, supporting a wide range of pharmaceutical and biotechnology clients. Both companies remain fully committed to delivering uninterrupted, high-quality services to all clients.

"We are proud to join forces with Biomapas, an organization that shares our dedication to innovation, quality, and patient safety," said Aytek Dağıstanlı, CEO of Delta PV. "This partnership will allow us to scale our solutions and continue delivering outstanding value to our clients across global markets."

In October 2024, Carbyne Equity Partners became a strategic shareholder in Biomapas with the goal of accelerating the company's global growth. The acquisition of Delta PV marks the first strategic step following this partnership and reflects the shared ambition to scale Biomapas' services in key markets.

"Delta PV brings deep regional knowledge, scientific strength, and additional digital capabilities to Biomapas. This partnership reflects the ambition we share — to build a truly global platform in pharmacovigilance and life sciences services," said Alexander Winterling, Chairman of the Board at Biomapas and Managing Partner at Carbyne Equity Partners.